Navigation Links
Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
Date:11/12/2013

ent. 

About Evolocumab (AMG 145)
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).1 PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.2 Evolocumab, being developed by Amgen scientists, is designed to bind to PCSK9 and inhibit PCSK9 binding to LDL receptors on the liver's surface. In the absence of PCSK9, there are more LDL receptors on the surface of the liver to remove LDL-C from the blood.1

Amgen has obtained the issuance of two U.S. patents related to evolocumab: USP 8,030,457 and USP 8,563,698. These patents will expire in 2029 but some extension period may be available, subject to certain regulatory conditions and statutory provisions for patent term extension.  

About PROFICIO: The Evolocumab Clinical Trial Program
PROFICIO, which stands for the Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different POpulations, is a large and comprehensive clinical trial program evaluating evolocumab. Phase 3 clinical trials for evolocumab are currently underway and build upon the Phase 2 studies.

The Phase 3 program includes 13 trials, with a combined planned enrollment of more than 28,000 patients. The Phase 3 studies will evaluate evolocumab administered every two weeks and monthly in multiple patient populations, including in combination with statins in patients with hyperlipidemia (LAPLACE-2), in patients with hyperlipidemia who cannot tolerate statins (GAUSS-2), as a stand-alone treatment in patients with hyperlipidemia (MENDEL-2), and in patients whose elevated cholesterol is caused by genetic disorders called heterozygous (RUTHERFORD-2) and homozygous (TESLA and TAUSSIG) familial hypercholesterolemia.

Five s
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
2. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
3. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
4. Amgen And Servier Complete Product Collaboration Transaction
5. Amgen Announces 2013 Third Quarter Dividend
6. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
7. Amgen And Servier Announce Product Collaboration
8. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
9. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
10. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
11. Amgen Announces 2013 Second Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... - Following the announcement on April 30, 2009, of ... Bionics Inc. ("Victhom", TSX: VHB) and Otto Bock HealthCare ... the transaction contemplated by the partnership agreement and the ... concurrent restructuring of its outstanding convertible debentures by way ...
... Fortune Magazine has named Neogen Corporation (Nasdaq: NEOG ... best stocks to retire on." , , Fortune ... to assemble a diversified, dependable portfolio of stocks for the long ... but also hold steady during darker times." , , ...
... Investors in a Financial Crisis, Draws Regional Biopharmaceutical Executives, ... 18 Biotech companies throughout the country are reeling ... 370 small-cap funds slated to run out of cash ... concluded during a life sciences symposium presented by ...
Cached Biology Technology:Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 2Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 3Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 4Neogen Named to Fortune's List of 40 Stocks 'To Retire On' 2Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 2Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 3Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 4Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 5
(Date:4/16/2014)... of a leaf looks like one seamless surface; however, ... of a patchwork of cells in a variety of ... take on their own unique forms, Caltech biologist Elliot ... pinpoint the shape-controlling factors in pavement cells, which are ... plants. They found that these unusual shapes were the ...
(Date:4/16/2014)... "brush border" a densely packed array of ... of the cells that line our intestines., Vanderbilt ... build this specialized structure, which is critical for ... published April 10 in the journal Cell ... brush border assembly and increase our understanding of ...
(Date:4/16/2014)... Geologic and soil processes are to blame for significant ... to a study published recently in the Journal ... soil samples from all corners of Ohio showed that ... level of concern recommended by the U.S. Environmental Protection ... the authors, who note that regulatory levels typically are ...
Breaking Biology News(10 mins):For cells, internal stress leads to unique shapes 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4
... its workshop on ,Update on pluripotent stem cells (hESC and ... culture of pluripotent stem cells,. The objective of the course ... on the state of the art of pluripotent stem cells. ... days 9-12 February is to provide the participants with the ...
... has launched Illuminea, a new quarterly newsletter for academic ... up-to-date with the latest developments at OUP and across ... for Journals at OUP, and member of the Editorial ... library community we have developed a strong and broad ...
... levels of DNA damage have for the first time been ... the inherited, progressive nervous system disease called Friedreich,s ataxia (FRDA), ... the University of Pittsburgh Cancer Institute (UPCI). The findings, ... the molecular abnormalities that lead to the disease, as well ...
Cached Biology News:Update on pluripotent stem cells (hESC and iPS) 2Excess DNA damage found in cells of patients with Friedreich's ataxia 2
... output accessory lessens the expensive task ... laboratories with multiple mass spectrometers. It ... from Agilent 1100 Series LC/MSD quadrupole ... transmits the analog data directly to ...
... SOS Protein Solubility Service, We deliversoluble ... New SOS technology yields the best soluble ... applied on each clone submitted , Powerful ... ,The new protein Solubility Optimization Service (SOS) ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
Biology Products: